Leerink Partners on Akebia Therapeutics (AKBA): approval of TVTX's Filspari in FSGS provides positive readthrough
Tweet Send to a Friend
Leerink Partners analyst Roanna Ruiz reiterated an Outperform rating and $3.00 price target on Akebia Therapeutics (NASDAQ: AKBA)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
